

Supporting Information  
for  
**A straightforward metal-free synthesis of  
2-substituted thiazolines in air**

Michael Trose, Faïma Lazreg, Mathieu Lesieur and Catherine S. J. Cazin\*

School of Chemistry University of St Andrews, St Andrews, KY16 9ST, United Kingdom

Fax: (+) 44 (0) 1334 463808; E-mail: [cc111@st-andrews.ac.uk](mailto:cc111@st-andrews.ac.uk)

## Table of Contents

1	General considerations .....	S5
2	Optimisation of reaction conditions .....	S5
3	In Situ FTIR Spectroscopy .....	S7
	IR spectra of benzonitrile, <b>1a</b> .....	S7
	IR spectra of 2-Phenyl-4,5-dihydrothiazole, <b>4a</b> .....	S7
	Reaction between benzonitrile and cysteamine hydrochloride without base .....	S8
	Reaction between benzonitrile and cysteamine hydrochloride in the presence of NaOH .....	S10
4	Synthesis and characterisation of thiazolines .....	S11
	2-Phenyl-4,5-dihydrothiazole, <b>4a</b> .....	S11
	2-(4-Fluorophenyl)-4,5-dihydrothiazole, <b>4b</b> .....	S11
	2-(4-Chlorophenyl)-4,5-dihydrothiazole, <b>4c</b> .....	S12
	2-(4-Bromophenyl)-4,5-dihydrothiazole, <b>4d</b> .....	S12
	2- <i>p</i> -Tolyl-4,5-dihydrothiazole, <b>4e</b> .....	S12
	2-(4-Methoxyphenyl)-4,5-dihydrothiazole, <b>4f</b> .....	S13
	4-(4,5-Dihydrothiazol-2-yl)aniline, <b>4g</b> .....	S13
	2-(3-Bromophenyl)-4,5-dihydrothiazole, <b>4h</b> .....	S13
	2- <i>m</i> -Tolyl-4,5-dihydrothiazole, <b>4i</b> .....	S14
	3-(4,5-Dihydrothiazol-2-yl)aniline, <b>4j</b> .....	S14
	2-(3,5-Difluorophenyl)-4,5-dihydrothiazole, <b>4k</b> .....	S14
	2-(2-Chlorophenyl)-4,5-dihydrothiazole, <b>4l</b> .....	S15
	2-(2-Bromophenyl)-4,5-dihydrothiazole, <b>4m</b> .....	S15
	2-(4,5-Dihydrothiazol-2-yl)aniline, <b>4n</b> .....	S15
	2-(4-Chlorobenzyl)-4,5-dihydrothiazole, <b>4o</b> .....	S16
	2-Benzyl-4,5-dihydrothiazole, <b>4p</b> .....	S16
	2-(2-Bromobenzyl)-4,5-dihydrothiazole, <b>4q</b> .....	S16
	2-(Pyridin-2-yl)-4,5-dihydrothiazole, <b>4r</b> .....	S16
	2-(Pyridin-3-yl)-4,5-dihydrothiazole, <b>4s</b> .....	S17
	2-(Pyridin-4-yl)-4,5-dihydrothiazole, <b>4t</b> .....	S17
	2-(1 <i>H</i> -Pyrrol-2-yl)-4,5-dihydrothiazole, <b>4u</b> .....	S17
	2-(2-Furanyl)-4,5-dihydrothiazole, <b>4v</b> .....	S18
	2-(Pent-4-yn-1-yl)-4,5-dihydrothiazole, <b>4w</b> .....	S18
	2-Pentyl-4,5-dihydrothiazole, <b>4x</b> .....	S18
	2-Cyclohexyl-4,5-dihydrothiazole, <b>4y</b> .....	S19
5	NMR spectra .....	S20
	<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-phenyl-4,5-dihydrothiazole, <b>4a</b> .....	S20
	<sup>13</sup> C-{ <sup>1</sup> H} NMR (125.7 MHz, CDCl <sub>3</sub> , 298K) of 2-phenyl-4,5-dihydrothiazole, <b>4a</b> .....	S20
	<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, <b>4b</b> .....	S21

<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, <b>4b</b> .....	S21
<sup>19</sup> F-{ <sup>1</sup> H} NMR (376 MHz, 298K) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, <b>4b</b> .....	S22
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4-chlorophenyl)-4,5-dihydrothiazole, <b>4c</b> .....	S23
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(4-chlorophenyl)-4,5-dihydrothiazole, <b>4c</b> .....	S23
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4-bromophenyl)-4,5-dihydrothiazole, <b>4d</b> .....	S24
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(4-bromophenyl)-4,5-dihydrothiazole, <b>4d</b> .....	S24
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2- <i>p</i> -tolyl-4,5-dihydrothiazole, <b>4e</b> .....	S25
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2- <i>p</i> -tolyl-4,5-dihydrothiazole, <b>4e</b> .....	S25
<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4-methoxyphenyl)-4,5-dihydrothiazole, <b>4f</b> .....	S26
<sup>13</sup> C-{ <sup>1</sup> H} NMR (125.7 MHz, CDCl <sub>3</sub> , 298K) of 2-(4-methoxyphenyl)-4,5-dihydrothiazole, <b>4f</b> .....	S26
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 4-(4,5-dihydrothiazol-2-yl)aniline, <b>4g</b> .....	S27
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 4-(4,5-dihydrothiazol-2-yl)aniline, <b>4g</b> .....	S27
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(3-bromophenyl)-4,5-dihydrothiazole, <b>4h</b> .....	S28
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(3-bromophenyl)-4,5-dihydrothiazole, <b>4h</b> .....	S28
<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2- <i>m</i> -tolyl-4,5-dihydrothiazole, <b>4i</b> .....	S29
<sup>13</sup> C-{ <sup>1</sup> H} NMR (125.7 MHz, CDCl <sub>3</sub> , 298K) of 2- <i>m</i> -tolyl-4,5-dihydrothiazole, <b>4i</b> .....	S29
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 3-(4,5-dihydrothiazol-2-yl)aniline, <b>4j</b> .....	S30
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 3-(4,5-dihydrothiazol-2-yl)aniline, <b>4j</b> .....	S30
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, <b>4k</b> .....	S31
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, <b>4k</b> .....	S31
<sup>19</sup> F-{ <sup>1</sup> H} NMR (376 MHz, 298K) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, <b>4k</b> .....	S32
<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(2-chlorophenyl)-4,5-dihydrothiazole, <b>4l</b> .....	S33
<sup>13</sup> C-{ <sup>1</sup> H} NMR (125.7 MHz, CDCl <sub>3</sub> , 298K) of 2-(2-chlorophenyl)-4,5-dihydrothiazole, <b>4l</b> .....	S33
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(2-bromophenyl)-4,5-dihydrothiazole, <b>4m</b> .....	S34
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(2-bromophenyl)-4,5-dihydrothiazole, <b>4m</b> .....	S34
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4,5-dihydrothiazol-2-yl)aniline, <b>4n</b> .....	S35
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(4,5-dihydrothiazol-2-yl)aniline, <b>4n</b> .....	S35
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(4-chlorobenzyl)-4,5-dihydrothiazole, <b>4o</b> .....	S36
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(4-chlorobenzyl)-4,5-dihydrothiazole, <b>4o</b> .....	S36
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-benzyl-4,5-dihydrothiazole, <b>4p</b> .....	S37
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-benzyl-4,5-dihydrothiazole, <b>4p</b> .....	S37
<sup>1</sup> H NMR (500 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(2-bromobenzyl)-4,5-dihydrothiazole, <b>4q</b> .....	S38
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(2-bromobenzyl)-4,5-dihydrothiazole, <b>4q</b> .....	S38
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(pyridin-2-yl)-4,5-dihydrothiazole, <b>4r</b> .....	S39
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(pyridin-2-yl)-4,5-dihydrothiazole, <b>4r</b> .....	S39
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(pyridin-3-yl)-4,5-dihydrothiazole, <b>4s</b> .....	S40
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(pyridin-3-yl)-4,5-dihydrothiazole, <b>4s</b> .....	S40
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(pyridin-4-yl)-4,5-dihydrothiazole, <b>4t</b> .....	S41
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(pyridin-4-yl)-4,5-dihydrothiazole, <b>4t</b> .....	S41

<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(1 <i>H</i> -pyrrol-2-yl)-4,5-dihydrothiazole, <b>4u</b> .....	S42
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(1 <i>H</i> -pyrrol-2-yl)-4,5-dihydrothiazole, <b>4u</b> .....	S42
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(2-furanyl)-4,5-dihydrothiazole, <b>4v</b> .....	S43
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(2-furanyl)-4,5-dihydrothiazole, <b>4v</b> .....	S43
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-(pent-4-yn-1-yl)-4,5-dihydrothiazole, <b>4w</b> .....	S44
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-(pent-4-yn-1-yl)-4,5-dihydrothiazole, <b>4w</b> .....	S44
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-pentyl-4,5-dihydrothiazole, <b>4x</b> .....	S45
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-pentyl-4,5-dihydrothiazole, <b>4x</b> .....	S45
<sup>1</sup> H NMR (400 MHz, CDCl <sub>3</sub> , 298K, TMS) of 2-cyclohexyl-4,5-dihydrothiazole, <b>4y</b> .....	S46
<sup>13</sup> C-{ <sup>1</sup> H} NMR (75 MHz, CDCl <sub>3</sub> , 298K) of 2-cyclohexyl-4,5-dihydrothiazole, <b>4y</b> .....	S46
6    References.....	S47

## 1 General considerations

All reactions were carried out in air. All reagents were purchased and used as received.  $^1\text{H}$ ,  $^{13}\text{C}$ - $\{^1\text{H}\}$  and  $^{19}\text{F}$ - $\{^1\text{H}\}$  Nuclear Magnetic Resonance (NMR) spectra were recorded at 298K on a Bruker Avance 400 Ultrashield or on a Bruker Avance 500 Ultrashield spectrometer using the residual solvent peak for  $^{13}\text{C}$ - $\{^1\text{H}\}$  NMR ( $\text{CDCl}_3$ :  $\delta_{\text{C}} = 77.16$  ppm) and TMS as reference for  $^1\text{H}$  NMR. Gas chromatography (GC) analyses were performed on an Agilent 7890A apparatus equipped with a flame ionization detector and a (5%-phenyl)-methylpolysiloxane column (30 m, 320  $\mu\text{m}$ , film: 0.25  $\mu\text{m}$ ). IR measurements were performed on a ReactIR A15 system (Mettler Toledo Autochem) with a DiComp AgX FiberConduit probe (9.5 mm). Mass spectroscopy was performed by the EPSRC National Mass Spectrometry Service Centre at Swansea University, UK.


## 2 Optimisation of reaction conditions

Table S1. Optimisation of reaction conditions

<div><div></div><div><div><b>1a</b></div><div><b>3</b></div><div><b>4a</b></div></div></div>				
Entry	<b>3</b> (mmol)	Base (Loading)	Time (h)	Conversion (%)
1	1	NaOH (30 mol%)	16	> 99
2	1	NaOH (20 mol%)	16	> 99
3	1	NaOH (10 mol%)	16	> 99
4	1	CsOH (10 mol%)	16	> 99
5	1	KOH (10 mol%)	16	> 99
6	1	NaOH (5 mol%)	16	91
7	0.75	NaOH (20 mol%)	16	> 99
8	0.75	NaOH (20 mol%)	<b>2</b>	<b>&gt; 99 (98)<sup>c</sup></b>
9	0.75	NaOH (20 mol%)	1	94

<sup>a</sup> Reaction conditions: **1** (0.5 mmol), **3** (0.75-1 mmol), base-catalyst, 80 °C, 1-16h. <sup>b</sup> Conversion determined by GC, based on benzonitrile, average of 2 reactions. <sup>c</sup> Isolated yield.

**Table S2.** Comparison of sources of NaOH<sup>a</sup>



Entry	Base	Conversion <sup>b</sup> (%)
1	NaOH batch1	> 99
2	NaOH batch2	> 99
3	NaOH batch3	> 99
4	NaOH semiconductor grade	> 99

<sup>a</sup> Reaction conditions: **1** (0.5 mmol), **3** (0.75 mmol), NaOH (20 mol%), 80 °C, 2h.

<sup>b</sup> Conversion determined by GC, based on benzonitrile, average of 2 reactions.

### 3 In Situ FTIR Spectroscopy

Figure S1 IR spectra of benzonitrile, **1a**






Figure S2 IR spectra of 2-Phenyl-4,5-dihydrothiazole, **4a**




### Reaction between benzonitrile and cysteamine hydrochloride without base




PROCEDURE: In air, a 5 mL round bottom flask was charged with benzonitrile (19.4 mmol, 2.0 g) and cysteamine hydrochloride (29.1 mmol, 3.3 g). The mixture was heated at 80°C until cysteamine hydrochloride was completely melted. The probe was submerged in the reaction mixture and the IR measurements were started. The reaction was stirred (350 rpm) at 80°C for 1h under solvent-free conditions.

**Figure S3** 3D plot of *in situ* IR measurements of the reaction between **1a** and **3** without base.






**Figure S4** IR plot of the reaction between **1a** and **3** without base.




## Reaction between benzonitrile and cysteamine hydrochloride in the presence of NaOH




PROCEDURE: In air, a 5 mL round bottom flask was charged with benzonitrile (19.4 mmol, 2.0 g) and cysteamine hydrochloride (29.1 mmol, 3.3 g). The mixture was heated at 80 °C until cysteamine hydrochloride was completely melted. The probe was submerged inside of the reaction mixture and the IR measurements were started. After 5 minutes 20 mol % of NaOH (2 mmol, 80 mg) were added. The reaction was stirred (350 rpm) at 80 °C for 1h under solvent-free conditions.

**Figure S5** 3D plot of *in situ* IR measurements of the reaction between **1a** and **3** in the presence of NaOH.




**Figure S6** IR plot of the reaction between **1a** and **3** in the presence of NaOH.



## 4 Synthesis and characterisation of thiazolines

In air, a vial was charged with the nitrile (1 mmol), cysteamine hydrochloride (1.5 mmol) and NaOH (0.2 mmol). The reaction was stirred at 80 °C for the appropriate time under solvent-free conditions. The crude product was dissolved in ethyl acetate (2 mL) and water (10 mL) was added. The aqueous layer was then extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered and dried under vacuum to give the desired compound. The conversion was determined by GC analysis or by <sup>1</sup>H NMR.

### 2-Phenyl-4,5-dihydrothiazole, **4a**<sup>[1]</sup>




The general procedure yielded to the title compound as a yellow oil (153 mg, 98%).

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.85-7.82 (m, 2H, C<sub>Ar</sub>H), 7.47-7.38 (m, 3H, C<sub>Ar</sub>H), 4.45 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.40 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (125.7 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 168.6 (s, C<sup>IV</sup>), 133.5 (s, C<sup>IV</sup>), 131.3 (s, C<sub>Ar</sub>H), 128.7 (s, C<sub>Ar</sub>H), 128.6 (s, C<sub>Ar</sub>H), 65.5 (s, CH<sub>2</sub>), 33.9 (s, CH<sub>2</sub>).

### 2-(4-Fluorophenyl)-4,5-dihydrothiazole, **4b**<sup>[2]</sup>




The general procedure yielded to the title compound as a colourless oil (168 mg, 93%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.84-7.79 (m, 2H, C<sub>Ar</sub>H), 7.10-7.04 (m, 2H, C<sub>Ar</sub>H), 4.41 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>), 3.38 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 167.1 (s, C<sup>IV</sup>), 164.5 (d, <sup>1</sup>J<sub>CF</sub> = 251.5 Hz, C<sup>IV</sup>), 130.5 (d, <sup>4</sup>J<sub>CF</sub> = 8.7 Hz, C<sub>Ar</sub>H), 129.7 (d, <sup>5</sup>J<sub>CF</sub> = 3.6 Hz, C<sup>IV</sup>), 115.6 (d, <sup>3</sup>J<sub>CF</sub> = 22.2 Hz, C<sub>Ar</sub>H), 65.3 (s, CH<sub>2</sub>), 34.0 (s, CH<sub>2</sub>).

**$^{19}\text{F}$ - $\{^1\text{H}\}$  NMR (376 MHz, 298K):**  $\delta$  (ppm) = -108.73 (s, CF).

2-(4-Chlorophenyl)-4,5-dihydrothiazole, **4c**<sup>[1]</sup>




The general procedure yielded to the title compound as a colourless solid (179 mg, 91%).

**$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS):**  $\delta$  (ppm) = 7.78-7.75 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 7.39-7.37 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 4.47-4.43 (m, 2H,  $\text{CH}_2$ ), 3.45-3.40 (m, 2H,  $\text{CH}_2$ ).

**$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K):**  $\delta$  (ppm) = 167.6 (s,  $\text{C}^{\text{IV}}$ ), 137.5 (s,  $\text{C}^{\text{IV}}$ ), 132.0 (s,  $\text{C}^{\text{IV}}$ ), 129.9 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 129.0 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 65.6 (s,  $\text{CH}_2$ ), 34.2 (s,  $\text{CH}_2$ ).

**Melting point:** 53 °C

2-(4-Bromophenyl)-4,5-dihydrothiazole, **4d**<sup>[3]</sup>




The general procedure yielded to the title compound as a colourless solid (228 mg, 94%).

**$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS):**  $\delta$  (ppm) = 7.71-7.69 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 7.56-7.53 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 4.44 (t,  $^3J_{\text{HH}}$  = 8.4 Hz, 2H,  $\text{CH}_2$ ), 3.45-3.41 (m, 2H,  $\text{CH}_2$ ).

**$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K):**  $\delta$  (ppm) = 167.7 (s,  $\text{C}^{\text{IV}}$ ), 132.5 (s,  $\text{C}^{\text{IV}}$ ), 132.0 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 130.1 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 126.0 (s,  $\text{C}^{\text{IV}}$ ), 65.6 (s,  $\text{CH}_2$ ), 34.3 (s,  $\text{CH}_2$ ).

**Melting point:** 91 °C

2-*p*-Tolyl-4,5-dihydrothiazole, **4e**<sup>[1]</sup>




The general procedure yielded to the title compound as a colourless solid (158 mg, 89%).

**$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS):**  $\delta$  (ppm) = 7.74-7.71 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 7.21-7.19 (m, 2H,  $\text{C}_{\text{Ar}}\text{H}$ ), 4.43 (t,  $^3J_{\text{HH}}$  = 8.3 Hz, 2H,  $\text{CH}_2$ ), 3.38 (t,  $^3J_{\text{HH}}$  = 8.3 Hz, 2H,  $\text{CH}_2$ ), 2.37 (s, 3H,  $\text{CH}_3$ ).

**$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K):**  $\delta$  (ppm) = 168.6 (s,  $\text{C}^{\text{IV}}$ ), 141.7 (s,  $\text{C}^{\text{IV}}$ ), 130.9 (s,  $\text{C}^{\text{IV}}$ ), 129.4 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 128.6 (s,  $\text{C}_{\text{Ar}}\text{H}$ ), 65.4 (s,  $\text{CH}_2$ ), 33.9 (s,  $\text{CH}_2$ ), 21.7 (s,  $\text{CH}_3$ ).

**Melting point:** 42 °C

2-(4-Methoxyphenyl)-4,5-dihydrothiazole, **4f**<sup>[3]</sup>




The general procedure yielded to the title compound as a yellow solid (188 mg, 97%).

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.79-7.76 (m, 2H, C<sub>Ar</sub>H), 6.90-6.88 (m, 2H, C<sub>Ar</sub>H), 4.39 (t, <sup>3</sup>J<sub>HH</sub> = 8.2 Hz, 2H, CH<sub>2</sub>), 3.80 (s, 3H, OCH<sub>3</sub>), 3.35 (t, <sup>3</sup>J<sub>HH</sub> = 8.2 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (125.7 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 167.7 (s, C<sup>IV</sup>), 162.0 (s, C<sup>IV</sup>), 130.1 (s, C<sub>Ar</sub>H), 126.2 (s, C<sup>IV</sup>), 113.9 (s, C<sub>Ar</sub>H), 65.2 (s, CH<sub>2</sub>), 55.5 (s, OCH<sub>3</sub>), 33.8 (s, CH<sub>2</sub>).

**Melting point:** 53 °C

4-(4,5-Dihydrothiazol-2-yl)aniline, **4g**<sup>[4]</sup>




The general procedure yielded to the title compound as a pale yellow oil (166 mg, 93%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.65-7.63 (m, 2H, C<sub>Ar</sub>H), 6.64-6.61 (m, 2H, C<sub>Ar</sub>H), 4.40-4.36 (m, 2H, CH<sub>2</sub>), 3.98 (s, 2H, NH<sub>2</sub>), 3.36-3.32 (m, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 168.2 (s, C<sup>IV</sup>), 149.6 (s, C<sup>IV</sup>), 130.3 (s, C<sub>Ar</sub>H), 123.7 (s, C<sup>IV</sup>), 114.5 (s, C<sub>Ar</sub>H), 65.1 (s, CH<sub>2</sub>), 33.7 (s, CH<sub>2</sub>).

2-(3-Bromophenyl)-4,5-dihydrothiazole, **4h**<sup>[5]</sup>




The general procedure yielded to the title compound as a pale brown solid (226 mg, 94%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 8.00 (d, <sup>5</sup>J<sub>HH</sub> = 1.9 Hz, 1H, C<sub>Ar</sub>H), 7.72 (dt, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, <sup>5</sup>J<sub>HH</sub> = 1.4 Hz, 1H, C<sub>Ar</sub>H), 7.57 (dq, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, <sup>5</sup>J<sub>HH</sub> = 1.2 Hz, 1H, C<sub>Ar</sub>H), 7.26 (t, <sup>3</sup>J<sub>HH</sub> = 7.8 Hz, 1H, C<sub>Ar</sub>H), 4.44 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.42 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 167.2 (s, C<sup>IV</sup>), 135.4 (s, C<sup>IV</sup>), 134.2 (s, C<sub>Ar</sub>H), 131.4 (s, C<sub>Ar</sub>H), 130.2 (s, C<sub>Ar</sub>H), 127.3 (s, C<sub>Ar</sub>H), 122.8 (s, C<sup>IV</sup>), 65.5 (s, CH<sub>2</sub>), 34.2 (s, CH<sub>2</sub>).

**Melting point:** 45 °C

### 2-*m*-Tolyl-4,5-dihydrothiazole, **4i**<sup>[6]</sup>




The general procedure yielded to the title compound as a colourless oil (150 mg, 85%).

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.67 (s, 1H, C<sub>Ar</sub>H), 7.62 (d, <sup>3</sup>J<sub>HH</sub> = 7.3 Hz, 1H, C<sub>Ar</sub>H), 7.30-7.24 (m, 2H, C<sub>Ar</sub>H), 4.43 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.38 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 2.38 (s, 3H, CH<sub>3</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (125.7 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 168.8 (s, C<sup>IV</sup>), 138.5 (s, C<sup>IV</sup>), 133.4 (s, C<sup>IV</sup>), 132.1 (s, C<sub>Ar</sub>H), 129.0 (s, C<sub>Ar</sub>H), 128.6 (s, C<sub>Ar</sub>H), 125.9 (s, C<sub>Ar</sub>H), 65.4 (s, CH<sub>2</sub>), 33.8 (s, CH<sub>2</sub>), 21.5 (s, CH<sub>3</sub>).

### 3-(4,5-Dihydrothiazol-2-yl)aniline, **4j**<sup>[1]</sup>




The general procedure yielded to the title compound as a brown solid (176 mg, 99%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.20-7.13 (m, 3H, C<sub>Ar</sub>H), 6.74-6.71 (m, 1H, C<sub>Ar</sub>H), 4.40 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.79 (s, 2H, NH<sub>2</sub>), 3.35 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 168.8 (s, C<sup>IV</sup>), 146.8 (s, C<sup>IV</sup>), 134.3 (s, C<sup>IV</sup>), 129.5 (s, C<sub>Ar</sub>H), 118.9 (s, C<sub>Ar</sub>H), 117.9 (s, C<sub>Ar</sub>H), 114.4 (s, C<sub>Ar</sub>H), 65.2 (s, CH<sub>2</sub>), 33.7 (s, CH<sub>2</sub>).

**Melting point:** 66 °C

### 2-(3,5-Difluorophenyl)-4,5-dihydrothiazole, **4k**



The general procedure yielded to the title compound as a colourless solid (194 mg, 98%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.38-7.33 (m, 2H, C<sub>Ar</sub>H), 6.93-6.88 (m, 1H, C<sub>Ar</sub>H), 4.46 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>), 3.45 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>).


**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 166.5 (m, C<sup>IV</sup>), 163.0 (dd, <sup>1</sup>J<sub>CF</sub> = 249.9 Hz, <sup>3</sup>J<sub>CF</sub> = 14.2 Hz, C<sup>IV</sup>), 136.5 (t, <sup>3</sup>J<sub>CF</sub> = 10.2 Hz, C<sup>IV</sup>), 111.6 (dd, <sup>2</sup>J<sub>CF</sub> = 19.7 Hz, <sup>4</sup>J<sub>CF</sub> = 7.9 Hz, C<sub>Ar</sub>H), 106.6 (t, <sup>2</sup>J<sub>CF</sub> = 25.6 Hz, C<sub>Ar</sub>H), 65.5 (s, CH<sub>2</sub>), 34.4 (s, CH<sub>2</sub>).

**<sup>19</sup>F-{<sup>1</sup>H} NMR (376 MHz, 298K):**  $\delta$  (ppm) = -109.01 (s, CF).

**HRMS calcd. for C<sub>9</sub>H<sub>8</sub>F<sub>2</sub>NS (M+H)<sup>+</sup>** 200.0340 **found** 200.0342.

**Melting point:** 43 °C

## 2-(2-Chlorophenyl)-4,5-dihydrothiazole, **4l**<sup>[1]</sup>




The general procedure yielded to the title compound as a light yellow oil (180 mg, 91%).

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.60 (dd, <sup>3</sup>J<sub>HH</sub> = 7.6 Hz, <sup>5</sup>J<sub>HH</sub> = 1.8 Hz, 1H, C<sub>Ar</sub>H), 7.42 (dd, <sup>3</sup>J<sub>HH</sub> = 7.9 Hz, <sup>5</sup>J<sub>HH</sub> = 1.2 Hz, 1H, C<sub>Ar</sub>H), 7.32 (td, <sup>3</sup>J<sub>HH</sub> = 7.4 Hz, <sup>5</sup>J<sub>HH</sub> = 1.8 Hz, 1H, C<sub>Ar</sub>H), 7.27 (td, <sup>3</sup>J<sub>HH</sub> = 7.6 Hz, <sup>5</sup>J<sub>HH</sub> = 1.4 Hz, 1H, C<sub>Ar</sub>H), 4.46 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>), 3.44 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (125.7 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 166.2 (s, C<sup>IV</sup>), 133.1 (s, C<sup>IV</sup>), 132.5 (s, C<sup>IV</sup>), 131.1 (s, C<sub>Ar</sub>H), 130.8 (s, C<sub>Ar</sub>H), 130.6 (s, C<sub>Ar</sub>H), 126.8 (s, C<sub>Ar</sub>H), 65.3 (s, CH<sub>2</sub>), 34.9 (s, CH<sub>2</sub>).

## 2-(2-Bromophenyl)-4,5-dihydrothiazole, **4m**




The general procedure yielded to the title compound as a colourless oil (234 mg, 98%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.60 (dd, <sup>3</sup>J<sub>HH</sub> = 8.0 Hz, <sup>5</sup>J<sub>HH</sub> = 1.1 Hz, 1H, C<sub>Ar</sub>H), 7.52 (dd, <sup>3</sup>J<sub>HH</sub> = 7.6 Hz, <sup>5</sup>J<sub>HH</sub> = 1.8 Hz, 1H, C<sub>Ar</sub>H), 7.31 (td, <sup>3</sup>J<sub>HH</sub> = 7.6 Hz, <sup>5</sup>J<sub>HH</sub> = 1.2 Hz, 1H, C<sub>Ar</sub>H), 7.22 (td, <sup>3</sup>J<sub>HH</sub> = 8.0 Hz, <sup>5</sup>J<sub>HH</sub> = 1.8 Hz, 1H, C<sub>Ar</sub>H), 4.46 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>), 3.45 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 167.2 (s, C<sup>IV</sup>), 135.2 (s, C<sup>IV</sup>), 133.7 (s, C<sub>Ar</sub>H), 131.1 (s, C<sub>Ar</sub>H), 130.5 (s, C<sub>Ar</sub>H), 127.3 (s, C<sub>Ar</sub>H), 121.2 (s, C<sup>IV</sup>), 65.4 (s, CH<sub>2</sub>), 35.1 (s, CH<sub>2</sub>).

**HRMS calcd. for C<sub>9</sub>H<sub>9</sub>BrNS (M+H)<sup>+</sup>** 241.9634 **found** 241.9631.

## 2-(4,5-Dihydrothiazol-2-yl)aniline, **4n**<sup>[1]</sup>




The general procedure yielded to the title compound as a pale yellow oil (176 mg, 99%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.47 (d, <sup>3</sup>J<sub>HH</sub> = 8.0 Hz, 1H, C<sub>Ar</sub>H), 7.16 (t, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 1H, C<sub>Ar</sub>H), 6.68-6.64 (m, 2H, C<sub>Ar</sub>H), 6.17 (s, 2H, NH<sub>2</sub>), 4.49-4.45 (m, 2H, CH<sub>2</sub>), 3.26-3.22 (m, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 169.6 (s, C<sup>IV</sup>), 147.8 (s, C<sup>IV</sup>), 132.8 (s, C<sub>Ar</sub>H), 131.7 (s, C<sub>Ar</sub>H), 116.5 (s, C<sub>Ar</sub>H), 116.2 (s, C<sub>Ar</sub>H), 115.2 (s, C<sup>IV</sup>), 65.5 (s, CH<sub>2</sub>), 32.1 (s, CH<sub>2</sub>).

2-(4-Chlorobenzyl)-4,5-dihydrothiazole, **4o**<sup>[1]</sup>




The general procedure yielded to the title compound as a yellow oil (194 mg, 92%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.28 (d, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, C<sub>Ar</sub>H), 7.21 (d, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, C<sub>Ar</sub>H), 4.23 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.77 (s, 2H, CH<sub>2</sub>), 3.26 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 170.1 (s, C<sup>IV</sup>), 134.8 (s, C<sup>IV</sup>), 133.3 (s, C<sup>IV</sup>), 130.7 (s, C<sub>Ar</sub>H), 129.0 (s, C<sub>Ar</sub>H), 64.9 (s, CH<sub>2</sub>), 40.3 (s, CH<sub>2</sub>), 34.5 (s, CH<sub>2</sub>).

2-Benzyl-4,5-dihydrothiazole, **4p**<sup>[1]</sup>




The general procedure yielded to the title compound as a yellow oil (172 mg, 97%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.30-7.19 (m, 5H, C<sub>Ar</sub>H), 4.19-4.14 (m, 2H, CH<sub>2</sub>), 3.78 (s, 2H, CH<sub>2</sub>), 3.18-3.13 (m, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 170.1 (s, C<sup>IV</sup>), 136.1 (s, C<sup>IV</sup>), 129.1 (s, C<sub>Ar</sub>H), 128.5 (s, C<sub>Ar</sub>H), 127.0 (s, C<sub>Ar</sub>H), 64.6 (s, CH<sub>2</sub>), 40.7 (s, CH<sub>2</sub>), 34.1 (s, CH<sub>2</sub>).

2-(2-Bromobenzyl)-4,5-dihydrothiazole, **4q**




The general procedure yielded to the title compound as a colourless oil (232 mg, 91%).

**<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 7.54 (d, <sup>3</sup>J<sub>HH</sub> = 7.5 Hz, 1H, C<sub>Ar</sub>H), 7.32-7.30 (m, 1H, C<sub>Ar</sub>H), 7.26-7.23 (m, 1H, C<sub>Ar</sub>H), 7.12-7.08 (m, 1H, C<sub>Ar</sub>H), 4.21 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>), 3.95 (s, 2H, CH<sub>2</sub>), 3.24 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 169.0 (s, C<sup>IV</sup>), 136.2 (s, C<sup>IV</sup>), 133.0 (s, C<sub>Ar</sub>H), 131.3 (s, C<sub>Ar</sub>H), 128.9 (s, C<sub>Ar</sub>H), 127.7 (s, C<sub>Ar</sub>H), 125.0 (s, C<sup>IV</sup>), 64.8 (s, CH<sub>2</sub>), 40.8 (s, CH<sub>2</sub>), 34.2 (s, CH<sub>2</sub>).

**HRMS calcd. for C<sub>10</sub>H<sub>11</sub>BrNS (M+H)<sup>+</sup> 255.9790 found 255.9790.**

2-(Pyridin-2-yl)-4,5-dihydrothiazole, **4r**<sup>[1]</sup>



The general procedure yielded to the title compound as a colourless solid (159 mg, 97%).




**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 8.66 (s, 1H, C<sub>Ar</sub>H), 8.08-8.05 (m, 1H, C<sub>Ar</sub>H), 7.79-7.73 (m, 1H, C<sub>Ar</sub>H), 7.48-7.33 (m, 1H, C<sub>Ar</sub>H), 4.57-4.51 (m, 2H, CH<sub>2</sub>), 3.41-3.34 (m, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 171.1 (s, C<sup>IV</sup>), 151.3 (s, C<sup>IV</sup>), 149.4 (s, C<sub>Ar</sub>H), 136.7 (s, C<sub>Ar</sub>H), 125.5 (s, C<sub>Ar</sub>H), 121.6 (s, C<sub>Ar</sub>H), 65.9 (s, CH<sub>2</sub>), 32.7 (s, CH<sub>2</sub>).

**Melting point:** 92 °C

## 2-(Pyridin-3-yl)-4,5-dihydrothiazole, **4s**<sup>[1]</sup>




The general procedure yielded to the title compound as a yellow oil (158 mg, 96%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 9.04 (d, <sup>5</sup>J<sub>HH</sub> = 1.6 Hz, 1H, C<sub>Ar</sub>H), 8.68 (dd, <sup>3</sup>J<sub>HH</sub> = 4.8 Hz, <sup>5</sup>J<sub>HH</sub> = 1.6 Hz, 1H, C<sub>Ar</sub>H), 8.10 (dt, <sup>3</sup>J<sub>HH</sub> = 8.0 Hz, <sup>5</sup>J<sub>HH</sub> = 1.9 Hz, 1H, C<sub>Ar</sub>H), 7.35 (dd, <sup>3</sup>J<sub>HH</sub> = 8.0 Hz, <sup>5</sup>J<sub>HH</sub> = 4.8 Hz, 1H, C<sub>Ar</sub>H), 4.46 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 3.45 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 165.6 (s, C<sup>IV</sup>), 151.8 (s, C<sub>Ar</sub>H), 149.4 (s, C<sub>Ar</sub>H), 135.4 (s, C<sub>Ar</sub>H), 129.1 (s, C<sup>IV</sup>), 123.3 (s, C<sub>Ar</sub>H), 65.2 (s, CH<sub>2</sub>), 33.9 (s, CH<sub>2</sub>).

## 2-(Pyridin-4-yl)-4,5-dihydrothiazole, **4t**<sup>[1]</sup>




The general procedure yielded to the title compound as a colourless solid (157 mg, 96%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 8.70 (dd, <sup>3</sup>J<sub>HH</sub> = 4.5 Hz, <sup>5</sup>J<sub>HH</sub> = 1.7 Hz, 2H, C<sub>Ar</sub>H), 7.67 (dd, <sup>3</sup>J<sub>HH</sub> = 4.5 Hz, <sup>5</sup>J<sub>HH</sub> = 1.7 Hz, 2H, C<sub>Ar</sub>H), 4.50 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>), 3.47 (t, <sup>3</sup>J<sub>HH</sub> = 8.5 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 167.2 (s, C<sup>IV</sup>), 150.6 (s, C<sub>Ar</sub>H), 140.3 (s, C<sup>IV</sup>), 122.3 (s, C<sub>Ar</sub>H), 65.7 (s, CH<sub>2</sub>), 34.2 (s, CH<sub>2</sub>).

**Melting point:** 73 °C

## 2-(1H-Pyrrol-2-yl)-4,5-dihydrothiazole, **4u**<sup>[7]</sup>




The general procedure yielded to the title compound as a colourless solid (300 mg, 98%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 10.54 (s, 1H, NH), 6.90 (s, 1H, C<sub>Ar</sub>H), 6.64 (d, <sup>3</sup>J<sub>HH</sub> = 2.9 Hz, 1H, C<sub>Ar</sub>H), 6.23 (t, <sup>3</sup>J<sub>HH</sub> = 2.9 Hz, 1H, C<sub>Ar</sub>H), 4.35 (t, <sup>3</sup>J<sub>HH</sub> = 8.1 Hz, 2H, CH<sub>2</sub>), 3.38 (t, <sup>3</sup>J<sub>HH</sub> = 8.1 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 161.5 (s, C<sup>IV</sup>), 126.0 (s, C<sup>IV</sup>), 122.6 (s, C<sub>Ar</sub>H), 115.0 (s, C<sub>Ar</sub>H), 110.0 (s, C<sub>Ar</sub>H), 64.1 (s, CH<sub>2</sub>), 33.7 (s, CH<sub>2</sub>).

**Melting point:** 94 °C

2-(2-Furanyl)-4,5-dihydrothiazole, **4v**<sup>[6]</sup>




The general procedure yielded to the title compound as a yellow oil (291 mg, 95%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 7.52-7.51 (m, 1H, C<sub>Ar</sub>H), 6.88 (d, <sup>3</sup>J<sub>HH</sub> = 3.5 Hz, 1H, C<sub>Ar</sub>H), 6.46 (dd, <sup>3</sup>J<sub>HH</sub> = 3.5 Hz, <sup>5</sup>J<sub>HH</sub> 1.8 Hz, 1H, C<sub>Ar</sub>H), 4.37 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>), 3.34 (t, <sup>3</sup>J<sub>HH</sub> = 8.3 Hz, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 157.2 (s, C<sup>IV</sup>), 147.6 (s, C<sup>IV</sup>), 144.4 (s, C<sub>Ar</sub>H), 113.2 (C<sub>Ar</sub>H), 111.4 (C<sub>Ar</sub>H), 64.5 (s, CH<sub>2</sub>), 33.1 (s, CH<sub>2</sub>).

2-(Pent-4-yn-1-yl)-4,5-dihydrothiazole, **4w**




The general procedure yielded to the title compound as a colourless oil (132 mg, 87%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 4.24-4.19 (m, 2H, CH<sub>2</sub>), 3.31-3.21 (m, 2H, CH<sub>2</sub>), 2.65-2.61 (m, 2H, CH<sub>2</sub>), 2.31-2.27 (m, 2H, CH<sub>2</sub>), 2.00-1.93 (m, 1H, CH), 1.93-1.86 (m, 2H, CH<sub>2</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 170.8 (s, C<sup>IV</sup>), 83.6 (s, CH), 69.3 (s, C<sup>IV</sup>), 64.8 (s, CH<sub>2</sub>), 34.0 (s, CH<sub>2</sub>), 33.2 (s, CH<sub>2</sub>), 26.3 (s, CH<sub>2</sub>), 18.1 (s, CH<sub>2</sub>).

**HRMS calcd. for C<sub>8</sub>H<sub>12</sub>NS (M+H)<sup>+</sup> 154.0685 found 154.0683.**

2-Pentyl-4,5-dihydrothiazole, **4x**<sup>[8]</sup>




The general procedure yielded after flash chromatography (SiO<sub>2</sub>, pentane/ ethyl acetate 7:3) to the title compound as a colourless oil (85 mg, 55%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):** δ (ppm) = 4.21 (tt, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, <sup>5</sup>J<sub>HH</sub> = 1.4 Hz, 2H, CH<sub>2</sub>), 3.27 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 2.52-2.48 (m, 2H, CH<sub>2</sub>), 1.69-1.61 (m, 2H, CH<sub>2</sub>), 1.36-1.31 (m, 4H, CH<sub>2</sub>), 0.92-0.88 (m, 3H, CH<sub>3</sub>).

**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):** δ (ppm) = 172.0 (s, C<sup>IV</sup>), 64.8 (s, CH<sub>2</sub>), 34.6 (s, CH<sub>2</sub>), 34.0 (s, CH<sub>2</sub>), 31.6 (s, CH<sub>2</sub>), 27.5 (s, CH<sub>2</sub>), 22.6 (s, CH<sub>2</sub>), 14.2 (s, CH<sub>3</sub>).

**HRMS calcd. for C<sub>8</sub>H<sub>16</sub>NS (M+H)<sup>+</sup> 158.0998 found 158.0997.**

2-Cyclohexyl-4,5-dihydrothiazole, **4y**<sup>[8]</sup>




The general procedure yielded after flash chromatography (SiO<sub>2</sub>, pentane/ ethyl acetate 8:2) to the title compound as a colourless oil (77 mg, 45%).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 298K, TMS):**  $\delta$  (ppm) = 4.20 (td, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, <sup>5</sup>J<sub>HH</sub> = 1.1 Hz, 2H, CH<sub>2</sub>), 3.22 (t, <sup>3</sup>J<sub>HH</sub> = 8.4 Hz, 2H, CH<sub>2</sub>), 2.53-2.46 (m, 1H, CH), 1.97-1.93 (m, 2H, CH<sub>2</sub>), 1.81-1.76 (m, 2H, CH<sub>2</sub>), 1.70-1.65 (m, 1H, CH<sub>2</sub>), 1.57-1.16 (m, 5H, CH<sub>2</sub>).


**<sup>13</sup>C-{<sup>1</sup>H} NMR (75 MHz, CDCl<sub>3</sub>, 298K):**  $\delta$  (ppm) = 176.7 (s, C<sup>IV</sup>), 64.7 (s, CH<sub>2</sub>), 43.6 (s, CH), 33.3 (s, CH<sub>2</sub>), 31.8 (s, CH<sub>2</sub>), 26.2 (s, CH<sub>2</sub>).

## 5 NMR spectra


$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-phenyl-4,5-dihydrothiazole, **4a**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (125.7 MHz,  $\text{CDCl}_3$ , 298K) of 2-phenyl-4,5-dihydrothiazole, **4a**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, **4b**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, **4b**




$^{19}\text{F}\{-^1\text{H}\}$  NMR (376 MHz, 298K) of 2-(4-fluorophenyl)-4,5-dihydrothiazole, **4b**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4-chlorophenyl)-4,5-dihydrothiazole, **4c**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4-chlorophenyl)-4,5-dihydrothiazole, **4c**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4-bromophenyl)-4,5-dihydrothiazole, **4d**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4-bromophenyl)-4,5-dihydrothiazole, **4d**







$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-*p*-tolyl-4,5-dihydrothiazole, **4e**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-*p*-tolyl-4,5-dihydrothiazole, **4e**




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4-methoxyphenyl)-4,5-dihydrothiazole, **4f**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (125.7 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4-methoxyphenyl)-4,5-dihydrothiazole, **4f**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 4-(4,5-dihydrothiazol-2-yl)aniline, **4g**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 4-(4,5-dihydrothiazol-2-yl)aniline, **4g**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(3-bromophenyl)-4,5-dihydrothiazole, **4h**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(3-bromophenyl)-4,5-dihydrothiazole, **4h**




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-*m*-tolyl-4,5-dihydrothiazole, **4i**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (125.7 MHz,  $\text{CDCl}_3$ , 298K) of 2-*m*-tolyl-4,5-dihydrothiazole, **4i**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 3-(4,5-dihydrothiazol-2-yl)aniline, **4j**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 3-(4,5-dihydrothiazol-2-yl)aniline, **4j**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, **4k**



$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, **4k**




$^{19}\text{F}\{-^1\text{H}\}$  NMR (376 MHz, 298K) of 2-(3,5-difluorophenyl)-4,5-dihydrothiazole, **4k**







$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(2-chlorophenyl)-4,5-dihydrothiazole, **4l**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (125.7 MHz,  $\text{CDCl}_3$ , 298K) of 2-(2-chlorophenyl)-4,5-dihydrothiazole, **4l**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(2-bromophenyl)-4,5-dihydrothiazole, **4m**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(2-bromophenyl)-4,5-dihydrothiazole, **4m**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4,5-dihydrothiazol-2-yl)aniline, **4n**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4,5-dihydrothiazol-2-yl)aniline, **4n**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(4-chlorobenzyl)-4,5-dihydrothiazole, **4o**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(4-chlorobenzyl)-4,5-dihydrothiazole, **4o**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-benzyl-4,5-dihydrothiazole, **4p**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-benzyl-4,5-dihydrothiazole, **4p**




$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(2-bromobenzyl)-4,5-dihydrothiazole, **4q**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(2-bromobenzyl)-4,5-dihydrothiazole, **4q**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(pyridin-2-yl)-4,5-dihydrothiazole, **4r**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(pyridin-2-yl)-4,5-dihydrothiazole, **4r**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(pyridin-3-yl)-4,5-dihydrothiazole, **4s**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(pyridin-3-yl)-4,5-dihydrothiazole, **4s**







$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(pyridin-4-yl)-4,5-dihydrothiazole, **4t**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(pyridin-4-yl)-4,5-dihydrothiazole, **4t**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(1*H*-pyrrol-2-yl)-4,5-dihydrothiazole, **4u**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(1*H*-pyrrol-2-yl)-4,5-dihydrothiazole, **4u**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(2-furanyl)-4,5-dihydrothiazole, **4v**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(2-furanyl)-4,5-dihydrothiazole, **4v**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-(pent-4-yn-1-yl)-4,5-dihydrothiazole, **4w**




$^{13}\text{C}\{-^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-(pent-4-yn-1-yl)-4,5-dihydrothiazole, **4w**




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-pentyl-4,5-dihydrothiazole, **4x**




$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-pentyl-4,5-dihydrothiazole, **4x**



$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , 298K, TMS) of 2-cyclohexyl-4,5-dihydrothiazole, **4y**



$^{13}\text{C}$ - $\{^1\text{H}\}$  NMR (75 MHz,  $\text{CDCl}_3$ , 298K) of 2-cyclohexyl-4,5-dihydrothiazole, **4y**



## 6 References

- [1] X. Li, B. Zhou, J. Zhang, M. She, S. An, H. Ge, C. Li, B. Yin, J. Li and Z. Shi, *Eur. J. Org. Chem.* 2012, **8**,1626.
- [2] L. Wu, *E-Journal of Chemistry*, 2012, **9**, 1035.
- [3] U. Pathak, S. Bhattacharyya, V. Dhruwansh, L. K. Pandey, R. Tank and M. V. S. Suryanarayana, *Green Chem.*, 2011, **13**, 1648
- [4] S. H. Babcock and R. Adams, *J. Am. Chem. Soc.*, 1937, **59**, 2260.
- [5] S. F. Hojati, I. Mohammadpoor-Baltork, B. Maleki, M. Gholizadeh, F. Shafiezhadeh and M. Haghdous, *Can. J. Chemistry*, 2010, **88**, 135.
- [6] J. A. Seijas, M. P. Vázquez-Tato, J. Crecente-Campo, *Tetrahedron*, 2008, **64**, 9280.
- [7] B. George, E. P. Papadopoulos, *J. Org. Chem.*, 1977, **42**, 441.
- [8] A. I. Meyers and J. L. Durandetta, *J. Org. Chem.*, 1975, **40**, 2021.